Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2018

View Archived Issues

Targeting GPCR prevents pre-eclampsia

Eli Lilly initiates phase I study of its bispecific antibody LY-3415244

Open-source drug discovery yields malaria prevention leads

Amgen presents first-in-human data for AMG-330 in relapsed/refractory AML

IMGN-632 demonstrates initial safety and activity in patients with AML and BPDCN

GMI-1687, a novel inhibitor of E-selectin with promising activity in preclinical models of AML

Icagen and Roche collaborate to develop and commercialize therapy for neurological diseases

Topline results presented from ENCORE-PH phase IIb study in patients with NASH cirrhosis

Phase I data presented for AUTO-3 CAR T-cell therapy targeting CD19 and CD22

Phase II study of elafibranor in primary biliary cholangitis meets primary endpoint

Multidomain antibodies with breadth and potency protect mice from a wide array of influenza strains

Novel thiazolidine free fatty acid FFA2 receptor agonist with improved properties

Novel inhaled PI3Kdelta inhibitor with improved properties for respiratory disease treatment

Phase III EAGLE trial of Imfinzi in head and neck cancer does not meet primary endpoints

FDA approves use of Tecentriq with Avastin and chemotherapy for first-line NSCLC

4D Molecular Therapeutics enters gene therapy collaboration for degenerative retinal diseases

Phase III pediatric ADHD studies with SPN-812 meet primary endpoint

Taizhou Huayuan Medicinal Tech patents brain damage resistance compounds

Prostanoid EP2 and/or EP4 receptor antagonists identified at Idorsia Pharmaceuticals

Phase III study of plinabulin for CIN meets primary endpoint at interim analysis

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine divulge TLR7 agonists

Mitobridge synthesizes new USP30 inhibitors

Biogen exercises option to obtain BIIB-067 from Ionis for ALS

Urate transporter 1 inhibitors patented by Hinova Pharmaceuticals

Low-dose aspirin protects from experimental autoimmune encephalomyelitis

AbbVie stops enrollment in Rova-T SCLC trial on IDMC recommendation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...